Histamine H3 Receptor Antagonists for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials

Journal of Alzheimer's Disease

Volumn 48, Issue 3, 2015, Pages 667-671

  Kubo, Momoko ^a   Kishi, Taro ^a   Matsunaga, Shinji ^a   Iwata, Nakao ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Alzheimer's disease; histamine H3 receptor antagonist; meta analysis; systematic review

Indexed keywords

A 349821; ABT 288; BETAHISTINE; BURIMAMIDE; CIPROXIFAN; CLOBENPROPIT; CONESSINE; GSK 239512; HISTAMINE H3 RECEPTOR ANTAGONIST; IMPENTAMINE; IODOPHENPROPIT; PITOLISANT; PLACEBO; THIOPERAMIDE; UNCLASSIFIED DRUG; NOOTROPIC AGENT;

ALZHEIMER DISEASE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; MENTAL DISEASE ASSESSMENT; META ANALYSIS; MINI MENTAL STATE EXAMINATION; NEUROPSYCHIATRIC INVENTORY SCORE; NUMBERS NEEDED TO TREAT; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ALZHEIMER DISEASE; HISTAMINE H3 ANTAGONISTS; HUMANS; NOOTROPIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84943802641     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150393     Document Type: Review

References (19)

1. Matsunaga S, Kishi T, Iwata N (2015) Memantine monotherapy for Alzheimer's disease: A systematic review and meta-analysis. PLoS One 10, e0123289.
2. Matsunaga S, Kishi T, Iwata N (2015) Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: A systematic review and meta-analysis. Int J Neuropsychopharmacol 18, doi: 10. 1093/ijnp/pyu115
3. Di Santo SG, Prinelli F, Adorni F, Caltagirone C, Musicco M (2013) A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease. J Alzheimers Dis 35, 349-361.
4. Nikolic K, Filipic S, Agbaba D, Stark H (2014) Procognitive properties of drugs with single and multitargeting H3 receptor antagonist activities. CNS Neurosci Ther 20, 613-623.
5. Brioni JD, Esbenshade TA, Garrison TR, Bitner SR, Cowart MD (2011) Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease. J Pharmacol Exp Ther 336, 38-46.
6. Vohora D, Bhowmik M (2012) Histamine H3 receptor antagonists/ inverse agonists on cognitive and motor processes: Relevance to Alzheimer's disease, ADHD, schizophrenia, and drug abuse. Front Syst Neurosci 6, 72.
7. Nathan PJ, Boardley R, Scott N, Berges A, Maruff P, Sivananthan T, Upton N, Lowy MT, Nestor PJ, Lai R (2013) The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H(3) receptor antagonist in patients with mild to moderate Alzheimer's disease: A preliminary investigation. Curr Alzheimer Res 10, 240-251.
8. Grove RA, Harrington CM, Mahler A, Beresford I, Maruff P, Lowy MT, Nicholls AP, Boardley RL, Berges AC, Nathan PJ, Horrigan JP (2014) A randomized, double-blind, placebocontrolled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-tomoderate Alzheimer's disease. Curr Alzheimer Res 11, 47-58.
9. Haig GM, Pritchett Y, Meier A, Othman AA, Hall C, Gault LM, Lenz RA (2014) A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia. J Alzheimers Dis 42, 959-971.
10. Higgins J, Green S. (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5. 1. 0. The Cochrane Collaboration, http://www. cochrane-handbook. org.
11. Folstein MF, Robins LN, Helzer JE (1983) The Mini-Mental State Examination. Arch Gen Psychiatr 40, 812.
12. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and metaanalyses: The PRISMA statement. BMJ 339, b2535.
13. Tedford CE, Phillips JG, Gregory R, Pawlowski GP, Fadnis L, Khan MA, Ali SM, Handley MK, Yates SL (1999) Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands. J Pharmacol Exp Ther 289, 1160-1168.
14. EsbenshadeTA, Fox GB, KruegerKM, Baranowski JL, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan JB, Faghih R, Bennani YL, Williams M, Hancock AA (2004) Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist. Biochem Pharmacol 68, 933-945.
15. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 44, 2308-2314.
16. Lim YY, Ellis KA, Harrington K, Ames D, Martins RN, Masters CL, Rowe C, Savage G, Szoeke C, Darby D, Maruff P, The Aibl Research G (2012) Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. J Clin Exp Neuropsychol 34, 345-358.
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327, 557-560.
18. Cohen J (1988) Statistical power analysis in the behavioral sciences. Erlbaum, Hillsdale NJ.
19. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods Group, Cochrane Statistical Methods, Group (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343, d5928.